Getts
Daniel Getts, Chicago, IL US
Patent application number | Description | Published |
---|---|---|
20120076831 | COMPOSITIONS AND METHODS FOR INDUCTION OF ANTIGEN-SPECIFIC TOLERANCE - The present invention utilizes carrier particles to present antigen peptides and proteins to the immune system in such a way as to induce antigen specific tolerance. The carrier particle is designed in order to trigger an immune tolerance effect. The invention is useful for treatment of immune related disorders such as autoimmune disease, transplant rejection and allergic reactions. | 03-29-2012 |
Daniel R. Getts, Washington, DC US
Patent application number | Description | Published |
---|---|---|
20130302301 | ANTIBODY AND METHODS FOR SELECTIVE INHIBITION OF T-CELL RESPONSES - The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-αβ TCR antibodies and antibody fragments. Anti-αβ TCR antibodies are antibodies which bind to a αβ TCR. Anti-αβ TCR antibodies produced by the hybridomaTOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-αβ TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided. The present invention also provides methods of treating inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using a therapeutic amount of ex vivo expanded regulatory T-cells. | 11-14-2013 |
20130323319 | MODIFIED IMMUNE-MODULATING PARTICLES - The current invention involves the surprising finding that when carboxylated particles, such as carboxylated polystyrene, PLGA, or diamond particles are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same carboxylated particles. | 12-05-2013 |
20130330351 | ANTIBODY AND METHODS FOR SELECTIVE INHIBITION OF T-CELL RESPONSES - The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-αβ TCR antibodies and antibody fragments. Anti-αβ TCR antibodies are antibodies which bind to a αβ TCR. Anti-αβ TCR antibodies produced by the hybridoma TOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-αβ TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided | 12-12-2013 |
Daniel R. Getts, Alexandria, VA US
Patent application number | Description | Published |
---|---|---|
20130122015 | ANTIBODY AND METHODS FOR SELECTIVE INHIBITION OF T-CELL RESPONSES - The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-αβ TCR antibodies and antibody fragments. Anti-αβ TCR antibodies are antibodies which bind to a αβ TCR. Anti-αβ TCR antibodies produced by the hybridoma TOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-αβ TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided | 05-16-2013 |
20130273089 | ANTIBODY AND METHODS FOR SELECTIVE INHIBITION OF T-CELL RESPONSES - The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-αβ TCR antibodies and antibody fragments. Anti-αβ TCR antibodies are antibodies which bind to a αβ TCR. Anti-αβ TCR antibodies produced by the hybridomaTOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-αβ TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided. The present invention also provides methods of treating inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using a therapeutic amount of ex vivo expanded regulatory T-cells. | 10-17-2013 |
Lori A. Getts, Huntingdon Valley, PA US
Patent application number | Description | Published |
---|---|---|
20140017704 | LATERAL FLOW ASSAYS USING DNA DENDRIMERS - The present invention relates to novel lateral flow devices using DNA dendrimers, and the methods for detecting an analyte using the lateral flow devices. | 01-16-2014 |
Robert C. Getts, Hatfield, PA US
Patent application number | Description | Published |
---|---|---|
20130012405 | Circulating miRNA Biomaker Signatures - Methods for diagnosis and surveillance of complex multi-factorial disorders such as cancer by screening of easily accessible biomarkers are disclosed. Highly stable cell free Circulating Nucleic Acids (CNA) present as both RNA and DNA species have been discovered in the blood and plasma of humans. Correlations between tumor-associated genomic/epigenetic/transcriptional changes and alterations in CNA levels are strong predictors of the utility of this biomarker class as clinical indicators. Methods for using microRNAs (miRNAs) representing a class of naturally occurring small non-coding RNAs of 19-25 nt as markers that can associate their specific expression profiles with cancer development are disclosed. Methods for isolating plasma fractions for the study of miRNA biomarkers and for measurement of circulating miRNA levels are disclosed. | 01-10-2013 |